Tuberculosis

Last Updated: March 24, 2026
Social Issues- Mains

Social Issues- Mains

After Reading This Article You Can Solve This UPSC Mains Model Question:

“Evaluate the shift from ‘Symptom-based’ to ‘Molecular-based’ diagnostics in India’s National TB Elimination Programme. How does this technological leap address the challenge of Multi-Drug Resistant TB (MDR-TB)?” (15 Marks, GS-2 Social Justice)

Context

India aimed to eliminate TB by 2025, five years ahead of the Sustainable Development Goal (SDG 3.3) target of 2030. While India recorded the fastest global decline in TB incidence (21% reduction since 2015), it missed the 2025 elimination target.

Current Burden: India still accounts for 25% of global TB cases and 32% of global Multi-Drug Resistant TB (MDR-TB) cases.
Latest Theme (World TB Day 2026): “Yes! We Can End TB!”

Tuberculosis (TB): Clinical Overview

Pathogen: Mycobacterium tuberculosis (Bacterium).
Transmission: Airborne (droplets from coughing/sneezing).
Classification:
- Pulmonary TB: Affects lungs (most common and contagious).
- Extrapulmonary TB: Affects lymph nodes, bones, kidneys, or the brain (Meningitis).
- Latent TB: Infected but not ill; cannot spread the disease (25% of the global population has latent TB).

Key Government Initiatives for TB Elimination

National Strategic Plan (NSP) 2017-2025: A multi-pronged framework aiming to eliminate TB by 2025 (5 years ahead of the SDG 2030 target) through the pillars of Detect, Treat, Prevent, and Build (DTPB).
Nikshay Poshan Yojana (NPY): A flagship Direct Benefit Transfer (DBT) scheme that provides ₹500–₹1,000 per month to every notified TB patient for nutritional support throughout the duration of their treatment.
Pradhan Mantri TB Mukt Bharat Abhiyaan: A community-driven initiative that introduced Nikshay Mitras. It allows individuals, NGOs, and corporates to “adopt” TB patients and provide them with additional diagnostic, nutritional, and vocational support.
Universal Drug Susceptibility Testing (U-DST): A policy shift ensuring that every diagnosed TB patient is screened for drug resistance (using molecular tests like CB-NAAT or TrueNat) at the very start of treatment, rather than waiting for treatment failure.
Introduction of BPaLM Regimen: As of 2024-2025, India has rolled out the BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin), which reduces the treatment time for Multi-Drug Resistant TB (MDR-TB) from 20 months to just 6 months.
TB Mukt Panchayat Abhiyaan: A decentralized “Jan Andolan” (People’s Movement) that empowers Panchayati Raj Institutions to track cases, reduce stigma, and achieve “TB-Free” status at the village level through a certification and award system.

Major Challenges in TB Elimination

Drug Resistance (MDR/XDR-TB): India has the world’s highest burden of Multi-Drug Resistant TB. Treatment is long, expensive, and often has severe side effects, leading to patient non-compliance.
The “Social Determinants” Gap: Undernutrition remains the leading risk factor, responsible for nearly 40% of TB cases. Coupled with overcrowded housing and poor ventilation in urban slums, these socio-economic factors sustain the transmission cycle despite medical interventions.
Private Sector Fragmentation: A significant portion of patients first seek care from private practitioners. Gaps in mandatory notification, inconsistent treatment protocols, and delayed referrals to the government system often lead to “missing cases” and improper treatment.
Latent TB Pool: An estimated 350–400 million Indians have Latent TB Infection (LTBI). These individuals are not sick but carry the bacteria; without massive scaling of TB Preventive Treatment (TPT), this pool remains a “ticking time bomb” for future active cases.
Stigma and Delayed Diagnosis: Deep-rooted social stigma leads to the concealment of symptoms, particularly among women and marginalized groups. This results in delayed diagnosis, increased community transmission, and higher mortality rates before treatment even begins.

Global Achievements in TB Control: Comparative Analysis

Region/ Country	Key Achievement (2015–2024)	Primary Drivers & Strategies
African Region	-46% Mortality (Fastest global decline) & -28% Incidence.	HIV-TB Integration: 90% co-infected patients on Antiretroviral Therapy (ART).Fiscal Shift: Transitioned from donor aid to national funding.Community Outreach: Massive deployment of rural health workers.
European Region	-39% Incidence (Global leader in rate reduction).	Digital Health: Whole Genome Sequencing & video-based adherence tools.Modern Regimens: All-oral 6-month treatments.Targeted Screening: Focus on migrants, prisoners, and elderly.
China	“Moderate-to-Low” Prevalence status (WHO 2025).	Zero-TB Communities: Mass screening + preventive treatment (TPT).AI-Smart Screening: 40% faster diagnosis using AI-chest X-rays.Governance: Three-tier network linking CDC, hospitals, and clinics.

Way Forward for TB Elimination

Scaling TB Preventive Treatment (TPT): Transition from just treating active cases to aggressively managing Latent TB. Expanding TPT to all household contacts of pulmonary TB patients is critical to exhausting the reservoir of future cases.
Integrating “One Health” Approach: Addressing TB not just as a respiratory disease but as a comorbidity-linked crisis. This involves mandatory screening for Diabetes, HIV, and tobacco use, which significantly increase the risk of treatment failure.
Strengthening Nutritional Security: Moving beyond the ₹1,000 DBT to direct food fortification and high-protein ration kits for vulnerable families. Addressing undernutrition is the most effective “social vaccine” against TB.
Private-Public Mix (PPM) Optimization: Universalizing the “Patient Provider Support Agencies” (PPSA) model to ensure that every patient treated in the private sector is notified, tracked, and provided with free government-funded molecular diagnostics and drugs.
R&D for an Adult Vaccine: Since the 100-year-old BCG vaccine loses efficacy in adults, India must fast-track indigenous clinical trials for candidates like VPM1002 or MTBVAC to provide long-term community immunity.
Community-Led Advocacy (Jan Andolan): Leveraging the Panchayati Raj Institutions and “Ni-kshay Mitras” to de-stigmatize the disease. Transforming TB elimination from a medical program into a social movement is the only way to reach the “missing millions.”

Conclusion

To end TB by 2030, India must shift from a clinical approach to a socio-technological movement, leveraging adult vaccines, AI-driven diagnostics, and nutritional sovereignty to ensure a “TB-Mukt Bharat.”